Dr. Jacobson Weiss received her PhD. in 2008 from the Hebrew University at Jerusalem in radiochemistry and molecular imaging, under the supervision of Prof. Eyal Mishani. Her research thesis was to explore the potential of the EGF and androgen receptors as targets for molecular imaging in order to monitor cancer treatment efficiency by developing novel PET labeled biomarkers. Dr. Jacobson Weiss has designed and synthesized novel EGFR and AR ligands for PET molecular imaging and developed and used new labeling methods.
From 2008 to 2011 Dr. Jacobson Weiss trained as a postdoc at NIBIB/NIH in Bethesda, Maryland. The main projects she focused on during her postdoc were imaging of chemokine receptor CXCR4 by small molecules and peptides and imaging of prokineticin receptor.
In 2011 Dr. Jacobson Weiss returned to Hadassah Medical Organization in Jerusalem, Israel, to be the head of the radiochemistry and chemistry group of the cyclotron unit, and supervised both clinical production of PET tracers as well as some research. After two and a half years, Dr. Jacobson Weiss came back to the NIBIB/NIH in order to focus on research and development of new radiotracers. Her current projects include imaging of Tenascin-C and labeling CXCR4 antagonist T140 derivatives for clinical application.